Daily Mail Stock Watch – Open Orphan #ORPH – October 30th 2020 October 31, 2020 – Posted in: Open Orphan (ORPH)
Daily Mail Stock Watch – Open Orphan #ORPH – October 30th 2020
Continue reading
Daily Mail Stock Watch – Open Orphan #ORPH – October 30th 2020
Continue readingOpen Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce a new 2-year contract with a tier 1 German pharmaceutical company which is one of Europe’s top research-driven pharmaceutical companies. The contract guarantees annual revenue, for the next two years, with work under the contract to commence this month. The contract will see…
Continue readingby Ellie Donnelly Open Orphan, a Europe-focused pharma services company specialising in rare disease and so-called orphan drugs, has signed a contract with a German-based research-driven pharmaceutical company. Open Orphan said the contract guarantees “significant” annual income, with work under the deal to commence this month. This contract will see Venn Life Sciences, part of Open Orphan, build upon its existing relationship with the German company with a new three year consultancy for Pharmacokinetic (PK)…
Continue readingOpen Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce the signing of a new 3-year contract with a tier 1 German pharmaceutical company which is one of Europe’s top research-driven pharmaceutical companies. The contract guarantees significant annual revenue with work under the contract to commence this month. This contract sees Venn Life Sciences (“Venn”), part of Open Orphan plc, build upon its strong existing relationship with this German pharmaceutical company with a new…
Continue reading